DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
MRS 2179 ammonium salt (HB4241)
Description:Selective P2Y1 antagonist. Inhibits platelet aggregation.
Purity:>98%
-
MTEP hydrochloride (HB0431)
Description:Potent, highly selective, non-competitive mGluR5 antagonist
Purity:>98%
-
Olanzapine (HB1786)
Description:5-HT2A and D2 antagonist. Potent DREADD agonist. Atypical antipsychotic.
Purity:>99%
-
PD 102807 (HB1509)
Description:Potent, selective M4 receptor antagonist. Promotes erythroid progenitors expansion.
Purity:>98%
-
Prochlorperazine dimaleate (HB1907)
Description:D2 receptor antagonist. Also 5-HT3 and nAChR antagonist.
Purity:>99%
-
Quetiapine hemifumarate (HB1803)
Description:5-HT2 and D2 antagonist. Atypical antipsychotic.
Purity:>99%
